Welcome to our dedicated page for Teladoc Health news (Ticker: TDOC), a resource for investors and traders seeking the latest updates and insights on Teladoc Health stock.
Teladoc Health reports news on its virtual care business, including financial results, segment performance, product innovation, technology investment, and governance updates. The company delivers and orchestrates care across patients, care providers, platforms, and partners through relationships with health plans, employers, providers, health systems, and consumers.
Recurring updates focus on Integrated Care, which includes virtual care solutions such as primary care, mental health, chronic care management, and telehealth enablement, and BetterHelp, the company’s direct-to-consumer online mental health offering. Company news also includes earnings calls, investor conference participation, board appointments and retirements, inducement equity awards, and strategic commentary on its clinical model and care-delivery platform.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Teladoc Health (TDOC) reported first quarter 2023 revenue of $629.2 million, reflecting an 11% year-over-year growth. However, the company posted a net loss of $69.2 million or ($0.42) per share, compared to a substantial loss of $6.67 billion in Q1 2022, which was mainly due to a prior goodwill impairment. Adjusted EBITDA decreased by 3% to $52.8 million. The Integrated Care segment saw revenue growth of 5% to $350 million, while BetterHelp revenue surged 21% to $279.3 million. Looking ahead, Teladoc projects Q2 2023 revenue of $635 - $660 million and expects a full year 2023 revenue between $2.575 - $2.675 billion. The financial outlook indicates potential improvement despite ongoing losses.
Teladoc Health is expanding its Provider-Based Care to include weight management and prediabetes programs, addressing a significant health issue in the U.S., where 42% of adults are estimated to live with obesity and 1 in 3 have prediabetes. This initiative builds on its existing diabetes and hypertension solutions, offering personalized care plans and coaching through digital tools. The new service aims to optimize medications like GLP-1 agonists and SGLT2 inhibitors, ensuring comprehensive support for individuals managing cardiometabolic health risks. Launching in Q3 2023, the expansion exemplifies Teladoc's commitment to improving health outcomes through innovative, evidence-based solutions.